- Home
- TII vs OBIO Comparison
TII vs OBIO Comparison
Compare TII & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TII | OBIO |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 214.1M | 237.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TII | OBIO |
|---|---|---|
| Price | $2.27 | $4.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 74.4K | ★ 285.8K |
| Earning Date | 03-20-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $75,461,000.00 | $2,818,000.00 |
| Revenue This Year | N/A | $36.43 |
| Revenue Next Year | N/A | $2.56 |
| P/E Ratio | $16.96 | ★ N/A |
| Revenue Growth | ★ 54.36 | 6.46 |
| 52 Week Low | $0.26 | $2.20 |
| 52 Week High | $3.39 | $6.30 |
Technical Indicators
Market Signals| Indicator | TII | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 47.51 |
| Support Level | N/A | $4.26 |
| Resistance Level | N/A | $4.64 |
| Average True Range (ATR) | 0.00 | 0.27 |
| MACD | 0.00 | -0.09 |
| Stochastic Oscillator | 0.00 | 7.92 |
Price Performance
Historical ComparisonAbout TII Titan Mining Corporation
Titan Mining Corp is a Canadian natural resources company. It is engaged in the acquisition, exploration, and development of mineral properties. The company owns an interest in the Empire State Mine in Northern New York State, United States. The Company operates one reportable segment, mineral production and exploration in the United States.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.